FEMPATCH

Clinical safety rating: caution

Comprehensive clinical and safety monograph for FEMPATCH (FEMPATCH).

How it works

Estradiol is a steroid hormone that binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, thereby replacing deficient endogenous estrogen in postmenopausal women.

What the body does with it

Metabolism	Estradiol is primarily metabolized in the liver via oxidation and conjugation; major enzymes include CYP3A4, CYP1A2, and CYP2C9, forming estrone, estriol, and their glucuronide and sulfate conjugates.
Excretion	Primarily renal as glucuronide and sulfate conjugates; less than 5% excreted unchanged in urine. Fecal excretion accounts for approximately 5-10% of the dose.
Half-life	Terminal elimination half-life is approximately 3-5 hours for estradiol. Transdermal administration results in sustained serum levels with a prolonged effective half-life due to continuous absorption; clinical context: allows once-weekly dosing.
Protein binding	Approximately 98% bound to serum albumin and sex hormone-binding globulin (SHBG).
Volume of Distribution	Volume of distribution is approximately 1.2 L/kg, indicating extensive distribution into tissues, including estrogen-responsive target organs.
Bioavailability	Transdermal bioavailability is approximately 100% as it bypasses first-pass hepatic metabolism; oral estradiol has variable bioavailability (5-20%) due to extensive first-pass metabolism.
Onset of Action	Therapeutic estrogenic effects (e.g., relief of vasomotor symptoms) typically occur within 2-4 weeks of continuous transdermal application.
Duration of Action	Each patch application provides continuous delivery of estradiol for 7 days. Clinical note: Replace patch weekly to maintain consistent serum levels.

Classification & Brands

Dosing & administration

Apply one patch transdermally twice weekly (every 3-4 days). Each patch delivers 0.025 mg, 0.0375 mg, 0.05 mg, 0.075 mg, or 0.1 mg estradiol per 24 hours, depending on strength.

Dosage form	FILM, EXTENDED RELEASE
Renal impairment	No specific dose adjustment recommended for GFR; however, use with caution in severe renal impairment due to potential fluid retention.
Liver impairment	Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment; monitor liver function.
Pediatric use	Not indicated for pediatric use. Safety and efficacy not established.
Geriatric use	Initiate at lowest effective dose. Monitor for adverse effects such as thromboembolic events and malignancy. Consider alternative therapies due to increased risk of dementia in women aged 65 years or older.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for FEMPATCH (FEMPATCH).

Breastfeeding	Estradiol is excreted into breast milk in low amounts (M/P ratio ~0.2). May reduce milk production and composition; use is contraindicated during breastfeeding. Alternative therapies preferred.
Teratogenic Risk	Estradiol is contraindicated in pregnancy. First trimester exposure associated with VACTERL anomalies, cardiovascular defects, and hypospadias. Second and third trimester exposure linked to reproductive tract abnormalities in female offspring (e.g., vaginal adenosis, clear cell adenocarcinoma) and potential neurodevelopmental effects.

Warnings & precautions

■ FDA Black Box Warning

Estrogen therapy increases the risk of endometrial cancer in women with an intact uterus; use with a progestin for endometrial protection is recommended unless hysterectomy has been performed.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Undiagnosed abnormal genital bleeding","Known, suspected, or history of breast cancer","Known or suspected estrogen-dependent neoplasia","Active venous thromboembolism (VTE) or history of VTE (e.g., DVT, PE)","Active arterial thromboembolism or history of (e.g., stroke, MI)","Hypersensitivity to estradiol or any component of the formulation","Hepatic impairment or disease","Pregnancy or suspected pregnancy"]

Clinical Precautions

Precautions

["Cardiovascular disorders: increased risk of stroke, DVT, and myocardial infarction","Malignant neoplasms: increased risk of endometrial and breast cancer","Dementia: increased risk in women aged 65 years or older","Gallbladder disease","Hypercalcemia in patients with breast cancer and bone metastases","Visual abnormalities (e.g., retinal vascular thrombosis)","Elevation of blood pressure","Hypothyroidism: may increase thyroid-binding globulin, requiring dose adjustment of thyroid replacement therapy"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

FEMPATCH

Clinical safety rating: caution

Comprehensive clinical and safety monograph for FEMPATCH (FEMPATCH).

How it works

What the body does with it

Metabolism	Estradiol is primarily metabolized in the liver via oxidation and conjugation; major enzymes include CYP3A4, CYP1A2, and CYP2C9, forming estrone, estriol, and their glucuronide and sulfate conjugates.
Excretion	Primarily renal as glucuronide and sulfate conjugates; less than 5% excreted unchanged in urine. Fecal excretion accounts for approximately 5-10% of the dose.
Half-life	Terminal elimination half-life is approximately 3-5 hours for estradiol. Transdermal administration results in sustained serum levels with a prolonged effective half-life due to continuous absorption; clinical context: allows once-weekly dosing.
Protein binding	Approximately 98% bound to serum albumin and sex hormone-binding globulin (SHBG).
Volume of Distribution	Volume of distribution is approximately 1.2 L/kg, indicating extensive distribution into tissues, including estrogen-responsive target organs.
Bioavailability	Transdermal bioavailability is approximately 100% as it bypasses first-pass hepatic metabolism; oral estradiol has variable bioavailability (5-20%) due to extensive first-pass metabolism.
Onset of Action	Therapeutic estrogenic effects (e.g., relief of vasomotor symptoms) typically occur within 2-4 weeks of continuous transdermal application.
Duration of Action	Each patch application provides continuous delivery of estradiol for 7 days. Clinical note: Replace patch weekly to maintain consistent serum levels.

Classification & Brands

Dosing & administration

Apply one patch transdermally twice weekly (every 3-4 days). Each patch delivers 0.025 mg, 0.0375 mg, 0.05 mg, 0.075 mg, or 0.1 mg estradiol per 24 hours, depending on strength.

Dosage form	FILM, EXTENDED RELEASE
Renal impairment	No specific dose adjustment recommended for GFR; however, use with caution in severe renal impairment due to potential fluid retention.
Liver impairment	Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment; monitor liver function.
Pediatric use	Not indicated for pediatric use. Safety and efficacy not established.
Geriatric use	Initiate at lowest effective dose. Monitor for adverse effects such as thromboembolic events and malignancy. Consider alternative therapies due to increased risk of dementia in women aged 65 years or older.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for FEMPATCH (FEMPATCH).

Breastfeeding	Estradiol is excreted into breast milk in low amounts (M/P ratio ~0.2). May reduce milk production and composition; use is contraindicated during breastfeeding. Alternative therapies preferred.
Teratogenic Risk	Estradiol is contraindicated in pregnancy. First trimester exposure associated with VACTERL anomalies, cardiovascular defects, and hypospadias. Second and third trimester exposure linked to reproductive tract abnormalities in female offspring (e.g., vaginal adenosis, clear cell adenocarcinoma) and potential neurodevelopmental effects.

Warnings & precautions

■ FDA Black Box Warning

Estrogen therapy increases the risk of endometrial cancer in women with an intact uterus; use with a progestin for endometrial protection is recommended unless hysterectomy has been performed.